154 related articles for article (PubMed ID: 38332225)
1. What's new about the tumor microenvironment of urothelial carcinoma?
Coelho JQ; Ramos MJ; Ranchor R; Pichel R; Guerra L; Miranda H; Simões J; Azevedo SX; Febra J; Araújo A
Clin Transl Oncol; 2024 Jul; 26(7):1549-1560. PubMed ID: 38332225
[TBL] [Abstract][Full Text] [Related]
2. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
3. Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
Aggen DH; Rosenberg JE
Nat Rev Clin Oncol; 2024 Jul; 21(7):487-488. PubMed ID: 38622410
[No Abstract] [Full Text] [Related]
4. Novel therapeutic targets in advanced urothelial carcinoma.
Rouanne M; Loriot Y; Lebret T; Soria JC
Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma: stem cells on the edge.
Brandt WD; Matsui W; Rosenberg JE; He X; Ling S; Schaeffer EM; Berman DM
Cancer Metastasis Rev; 2009 Dec; 28(3-4):291-304. PubMed ID: 20012172
[TBL] [Abstract][Full Text] [Related]
6. Urothelial carcinoma with abundant myxoid stroma: evidence for mucus production by cancer cells.
Gilg MM; Wimmer B; Ott A; Langner C
Virchows Arch; 2012 Jul; 461(1):99-101. PubMed ID: 22638768
[No Abstract] [Full Text] [Related]
7. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
8. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
10. Histologic grading of urothelial carcinoma: a reappraisal.
Cheng L; MacLennan GT; Lopez-Beltran A
Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
[TBL] [Abstract][Full Text] [Related]
11. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
Peng M
Front Immunol; 2022; 13():970885. PubMed ID: 36003383
[TBL] [Abstract][Full Text] [Related]
12. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture.
Cox RM; Schneider AG; Sangoi AR; Clingan WJ; Gokden N; McKenney JK
Am J Surg Pathol; 2009 Aug; 33(8):1213-9. PubMed ID: 19542871
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C
Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486
[TBL] [Abstract][Full Text] [Related]
14. Predicting progression of bladder urothelial carcinoma using microRNA expression.
Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
[TBL] [Abstract][Full Text] [Related]
15. [Molecular tumor board-urothelial cancer].
Hupe MC; Gakis G; Seiler R
Urologe A; 2019 Jul; 58(7):760-767. PubMed ID: 31172245
[TBL] [Abstract][Full Text] [Related]
16. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
17. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
Omran OM
J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
[TBL] [Abstract][Full Text] [Related]
18. A new era in the treatment of urothelial carcinoma.
Faltas B
Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
[TBL] [Abstract][Full Text] [Related]
19. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
20. S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers.
Suryavanshi M; Sanz-Ortega J; Sirohi D; Divatia MK; Ohe C; Zampini C; Luthringer D; Smith SC; Amin MB
Adv Anat Pathol; 2017 May; 24(3):151-160. PubMed ID: 28398953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
